370 related articles for article (PubMed ID: 12527709)
1. The role of CD10 staining in distinguishing invasive endometrial adenocarcinoma from adenocarcinoma involving adenomyosis.
Nascimento AF; Hirsch MS; Cviko A; Quade BJ; Nucci MR
Mod Pathol; 2003 Jan; 16(1):22-7. PubMed ID: 12527709
[TBL] [Abstract][Full Text] [Related]
2. Adenomyosis involved by endometrial adenocarcinoma is a significant risk factor for deep myometrial invasion.
Ismiil N; Rasty G; Ghorab Z; Nofech-Mozes S; Bernardini M; Ackerman I; Thomas G; Covens A; Khalifa MA
Ann Diagn Pathol; 2007 Aug; 11(4):252-7. PubMed ID: 17630108
[TBL] [Abstract][Full Text] [Related]
3. Adenomyosis is associated with myometrial invasion by FIGO 1 endometrial adenocarcinoma.
Ismiil ND; Rasty G; Ghorab Z; Nofech-Mozes S; Bernardini M; Thomas G; Ackerman I; Covens A; Khalifa MA
Int J Gynecol Pathol; 2007 Jul; 26(3):278-83. PubMed ID: 17581412
[TBL] [Abstract][Full Text] [Related]
4. CD10 imunostaining does not distinguish endometrial carcinoma invading myometrium from carcinoma involving adenomyosis.
Srodon M; Klein WM; Kurman RJ
Am J Surg Pathol; 2003 Jun; 27(6):786-9. PubMed ID: 12766582
[TBL] [Abstract][Full Text] [Related]
5. CD10 immunostaining distinguishes atypical polypoid adenomyofibroma (atypical polypoid adenomyoma) from endometrial carcinoma invading the myometrium.
Ohishi Y; Kaku T; Kobayashi H; Aishima S; Umekita Y; Wake N; Tsuneyoshi M
Hum Pathol; 2008 Oct; 39(10):1446-53. PubMed ID: 18619643
[TBL] [Abstract][Full Text] [Related]
6. Endometrial adenocarcinoma involving adenomyosis without true myometrial invasion is characterized by frequent preceding estrogen therapy, low histologic grades, and excellent prognosis.
Mittal KR; Barwick KW
Gynecol Oncol; 1993 May; 49(2):197-201. PubMed ID: 8504988
[TBL] [Abstract][Full Text] [Related]
7. CD10 and calretinin staining of endocervical glandular lesions, endocervical stroma and endometrioid adenocarcinomas of the uterine corpus: CD10 positivity is characteristic of, but not specific for, mesonephric lesions and is not specific for endometrial stroma.
McCluggage WG; Oliva E; Herrington CS; McBride H; Young RH
Histopathology; 2003 Aug; 43(2):144-50. PubMed ID: 12877729
[TBL] [Abstract][Full Text] [Related]
8. IFITM1 Is Superior to CD10 as a Marker of Endometrial Stroma in the Evaluation of Myometrial Invasion by Endometrioid Adenocarcinoma.
Busca A; Djordjevic B; Giassi A; Parra-Herran C
Am J Clin Pathol; 2016 Apr; 145(4):486-96. PubMed ID: 27124937
[TBL] [Abstract][Full Text] [Related]
9. P53 expression in adenomyosis in endometrial carcinoma patients.
Taskin M; Lallas TA; Shevchuk M; Barber HR
Gynecol Oncol; 1996 Aug; 62(2):241-6. PubMed ID: 8751556
[TBL] [Abstract][Full Text] [Related]
10. Utility of CD10 in distinguishing between endometrial stromal sarcoma and uterine smooth muscle tumors: an immunohistochemical comparison of 34 cases.
Chu PG; Arber DA; Weiss LM; Chang KL
Mod Pathol; 2001 May; 14(5):465-71. PubMed ID: 11353058
[TBL] [Abstract][Full Text] [Related]
11. Endocervical adenocarcinomas with prominent endometrial or endomyometrial involvement simulating primary endometrial carcinomas: utility of HPV DNA detection and immunohistochemical expression of p16 and hormone receptors to confirm the cervical origin of the corpus tumor.
Yemelyanova A; Vang R; Seidman JD; Gravitt PE; Ronnett BM
Am J Surg Pathol; 2009 Jun; 33(6):914-24. PubMed ID: 19295407
[TBL] [Abstract][Full Text] [Related]
12. Immunoprofile of endocervical and endometrial stromal cells and its potential application in localization of tumor involvement.
Barroeta JE; Pasha TL; Acs G; Zhang PJ
Int J Gynecol Pathol; 2007 Jan; 26(1):76-82. PubMed ID: 17197901
[TBL] [Abstract][Full Text] [Related]
13. Diffusely infiltrating endometrial carcinomas with no stromal response: report of a series, including cases with cervical and ovarian involvement and emphasis on the potential for misdiagnosis.
Kalyanasundaram K; Ganesan R; Perunovic B; McCluggage WG
Int J Surg Pathol; 2010 Apr; 18(2):138-43. PubMed ID: 19117974
[TBL] [Abstract][Full Text] [Related]
14. Cellular retinol-binding protein-1 expression in endometrial stromal cells: physiopathological and diagnostic implications.
Orlandi A; Ferlosio A; Ciucci A; Sesti F; Lifschitz-Mercer B; Gabbiani G; Spagnoli LG; Czernobilsky B
Histopathology; 2004 Nov; 45(5):511-7. PubMed ID: 15500655
[TBL] [Abstract][Full Text] [Related]
15. The significance of tumor involved adenomyosis in otherwise low-stage endometrioid adenocarcinoma.
Hanley KZ; Dustin SM; Stoler MH; Atkins KA
Int J Gynecol Pathol; 2010 Sep; 29(5):445-51. PubMed ID: 20736770
[TBL] [Abstract][Full Text] [Related]
16. Endometrial adenocarcinoma with variable-level myometrial involvement limited to adenomyosis: a clinicopathologic study of 23 cases.
Jacques SM; Lawrence WD
Gynecol Oncol; 1990 Jun; 37(3):401-7. PubMed ID: 2351325
[TBL] [Abstract][Full Text] [Related]
17. Paraffin-section detection of CD10 in 505 nonhematopoietic neoplasms. Frequent expression in renal cell carcinoma and endometrial stromal sarcoma.
Chu P; Arber DA
Am J Clin Pathol; 2000 Mar; 113(3):374-82. PubMed ID: 10705818
[TBL] [Abstract][Full Text] [Related]
18. Serous endometrial intraepithelial carcinoma arising in adenomyosis: a report of 5 cases.
Abushahin N; Zhang T; Chiang S; Zhang X; Hatch K; Zheng W
Int J Gynecol Pathol; 2011 May; 30(3):271-81. PubMed ID: 21464726
[TBL] [Abstract][Full Text] [Related]
19. Increased expression of the adult stem cell marker Musashi-1 in endometriosis and endometrial carcinoma.
Götte M; Wolf M; Staebler A; Buchweitz O; Kelsch R; Schüring AN; Kiesel L
J Pathol; 2008 Jul; 215(3):317-29. PubMed ID: 18473332
[TBL] [Abstract][Full Text] [Related]
20. Serous carcinoma arising from uterine adenomyosis/adenomyotic cyst of the cervical stump: a report of 3 cases.
Lu B; Chen Q; Zhang X; Cheng L
Diagn Pathol; 2016 Jun; 11(1):46. PubMed ID: 27260518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
